Ontario’s health minister says the province will now publicly fund a new treatment for advanced-stage prostate cancer.
Health Canada approved Pluvicto in August 2022, but patients have been waiting since then for provincial health plans to announce coverage.
Health Minister Sylvia Jones says Ontario is the first Canadian jurisdiction to publicly fund and administer the treatment.
Get weekly health news
Ontario says it is working with hospitals to implement Pluvicto as a standard treatment for patients with advanced-stage prostate cancer and it is expected to be available to eligible patients at most of the province’s cancer treatment centres in the next few months.
- Okanagan wildfires force more evacuation orders as First Nation assesses losses
- Another Canadian is preparing to head to space, this time for ISS mission
- Montreal self-serve bakery vandalized again as anti-tech message left
- N.S. Liberal leadership hopefuls ready to rebuild during leadership campaign
-
![]()
Passengers scrambling to rebook flights as WestJet flight attendant strike kicks off -
![]()
WestJet, union representing flight attendants reach tentative agreement ending work stoppage -
![]()
Flight attendants hit the picket line after CUPE, WestJet fail reach a new contract -
![]()
Russia-Ukraine war: Massive strikes exchanged as U.S. makes effort to renew negotiations
Pluvicto is a targeted radioligand therapy, a radioactive drug that kills the specific cancer cells, and uses a medical isotope that is produced in Ontario.
Experts say radioligand therapy has lower side-effects than traditional radiation because it minimizes harm to healthy cells.
Comments
Want to discuss? Please read our Commenting Policy first.